Deepak L. Bhatt

Mar 30, 2025 | healio.com | Katie Kalvaitis |Richard Smith |Sergio Raposeiras-Roubín |Deepak L. Bhatt

• Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent TAVR. • Genital infections and hypotension were more common in the dapagliflozin group. CHICAGO — The first trial to evaluate use of an SGLT2 inhibitor in people undergoing transcatheter aortic valve replacement showed benefit with dapagliflozin compared with standard care alone, including in older patients.

Mar 29, 2025 | healio.com | Erik Swain |Richard Smith |Deepak L. Bhatt

• Bentracimab restored platelet function in patients on ticagrelor with major bleeding or undergoing urgent surgery. CHICAGO — Bentracimab, a recombinant human immunoglobulin G1 monoclonal antibody fragment, restored platelet function in patients on ticagrelor undergoing urgent surgery or with major bleeding, according to data from the REVERSE-IT trial. The phase 3 trial was presented at the American College of Cardiology Scientific Session. Deepak L.

Jan 24, 2025 | healio.com | Scott Buzby |Richard Smith |Deepak L. Bhatt

The year in thrombosis, CAD: New PCI populations and DAPT strategies• A speaker highlighted key advances in thrombosis and coronary disease treatment in 2024. • Topics included updated European guidelines for DAPT after PCI and an upcoming trial marrying coronary CT imaging and AI. Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top developments in thrombosis and coronary disease from 2024.

Jun 2, 2024 | jacc.org | John Gregson |Stuart J. Pocock |Stefan Anker |Deepak L. Bhatt

References1. "The analysis of survival data in nephrology: basic concepts and methods of Cox regression". Kidney Int . 2008;74:705-709. 2. "A proportional hazards model for the subdistribution of a competing risk". J Am Stat Assoc . 1999;94:496-509. 3. "Applying Cox regression to competing risks". Biometrics . 1995;51:524-532. 4. "Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation". Stat Med . 2014;33:4681-4694. 5. "R package InformativeCensoring.

May 17, 2024 | thelancet.com | Muhammad Usman |Deepak L. Bhatt |Ishaque Hameed |Stefan Anker

1. US Food and Drug AdministrationGuidance for industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2. European Medicines AgencyGuideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 3. Zinman B Wanner C Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-21284. Neal B Perkovic V Mahaffey KW et al.